Proteomic and Phosphoproteomic Changes of MAPK-Related Inflammatory Response in an Animal Model of Neuropathic Pain by Differential Target Multiplexed SCS and Low-Rate SCS

Autor: Cedeño DL, Tilley DM, Vetri F, Platt DC, Vallejo R
Jazyk: angličtina
Rok vydání: 2022
Předmět:
Zdroj: Journal of Pain Research, Vol Volume 15, Pp 895-907 (2022)
Druh dokumentu: article
ISSN: 1178-7090
Popis: David L Cedeño,1,2 Dana M Tilley,2 Francesco Vetri,3 David C Platt,1,2 Ricardo Vallejo1– 3 1Neuroscience, Illinois Wesleyan University, Bloomington, IL, USA; 2Research and Development, SGX Medical, Bloomington, IL, USA; 3Research Department, National Spine and Pain Centers, Bloomington, IL, USACorrespondence: Ricardo Vallejo; David L Cedeño, Email vallejo1019@yahoo.com; dclumbrera@gmail.comIntroduction: Neuropathic pain initiates an interplay of pathways, involving MAP kinases and NFκB-signaling, leading to expression of immune response factors and activation and inactivation of proteins via phosphorylation. Neuropathic pain models demonstrated that spinal cord stimulation (SCS) may provide analgesia by modulating gene and protein expression in neuroinflammatory processes. A differential target multiplexed programming (DTMP) approach was more effective than conventional SCS treatments at modulating these. This work investigated the effect of DTMP and low rate SCS (LR-SCS) on proteins associated with MAP kinases and NFκB-signaling relevant to neuroinflammation.Methods: Animals subjected to the spared nerve injury model (SNI) of neuropathic pain were treated continuously (48h) with either DTMP or LR-SCS. No-SNI and No-SCS groups were included as controls. Proteomics and phosphoproteomics of stimulated spinal cord tissues were performed via liquid chromatography/tandem mass spectrometry. Proteins were identified from mass spectra using bioinformatics. Expression levels and fold changes (No-SCS/No-SNI and SCS/No-SCS) were obtained from spectral intensities.Results: Analyses identified 7192 proteins, with 1451 and 705 significantly changed by DTMP and LR-SCS, respectively. Eighty-one proteins, including MAP kinases, facilitating NFκB-signaling as part of inflammatory processes were identified. The pain model significantly increased expression levels of complement pathway-related proteins (LBP, NRG1, APP, CFH, C3, C5), which were significantly reversed by DTMP. Expression levels of other complement pathway-related proteins (HMGB1, S100A8, S100A9, CRP, C4) were decreased by DTMP, although not significantly affected by SNI. Other proteins (ORM1, APOE, NG2, CNTF) involved in NFκB-signaling were increased by SNI and decreased by DTMP. Expression levels of phosphorylated protein kinases involved in NFκB-signaling (including MAP kinases, PKC, MARK1) were affected by the pain model and reverse modulated by DTMP. LR-SCS modulated inflammatory-related proteins although to a lesser extent than DTMP.Conclusion: Proteomic analyses support the profound effect of the DTMP approach on neuroinflammation via MAP kinases and NFκB-mediated signaling to alleviate neuropathic pain.Keywords: differential target multiplexed spinal cord stimulation, proteomics, neuropathic pain, neuroinflammation, mitogen activated protein kinase, nuclear factor-kappa B
Databáze: Directory of Open Access Journals